NALOXONE JUNO naloxone hydrochloride (as dihydrate) 400 micrograms/1 mL solution for injection, ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

naloxone juno naloxone hydrochloride (as dihydrate) 400 micrograms/1 ml solution for injection, ampoule

juno pharmaceuticals pty ltd - naloxone hydrochloride dihydrate, quantity: 440 microgram/ml (equivalent: naloxone hydrochloride?, qty 400 microgram/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by opioids including natural and synthetic opioids, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. naloxone hydrochloride injection is also indicated for the diagnosis of suspected acute opioid overdosage.

NALOXONE JUNO NEONATAL naloxone hydrochloride (as dihydrate) 40 micrograms/2 mL solution for injection, ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

naloxone juno neonatal naloxone hydrochloride (as dihydrate) 40 micrograms/2 ml solution for injection, ampoule

juno pharmaceuticals pty ltd - naloxone hydrochloride dihydrate, quantity: 22 microgram/ml (equivalent: naloxone hydrochloride?, qty 20 microgram/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by opioids including natural and synthetic opioids, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. naloxone hydrochloride injection is also indicated for the diagnosis of suspected acute opioid overdosage.

DECAPEPTYL triptorelin acetate 100 micrograms/1 mL solution for injection in 1mL pre-filled syringe with integrated needle Australia - English - Department of Health (Therapeutic Goods Administration)

decapeptyl triptorelin acetate 100 micrograms/1 ml solution for injection in 1ml pre-filled syringe with integrated needle

ferring pharmaceuticals pty ltd - triptorelin acetate, quantity: 100 microgram (equivalent: triptorelin, qty 95.6 microgram/ml) - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium chloride - decapeptyl 100 micrograms/1 ml is indicated for down-regulation and prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (art).,in clinical trials decapeptyl 100 micrograms/1 ml has been used in cycles where urinary and recombinant human follicle stimulating hormone (fsh) as well as human menopausal gonadotrophin (hmg) were used for stimulation.

SIGNIFOR pasireotide 900 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 900 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 1128.6 microgram (equivalent: pasireotide, qty 900 microgram) - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; tartaric acid - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 300 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 300 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 600 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 600 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 752.4 microgram (equivalent: pasireotide, qty 600 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; tartaric acid; mannitol - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SPIRIVA RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

spiriva respimat tiotropium 2.5 micrograms/actuation solution for inhalation cartridge

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: spiriva respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). spiriva respimat is indicated for the prevention of copd exacerbations.,asthma: spiriva respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

DOUBLUTS dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

doubluts dutasteride 500 microgram and tamsulosin hydrochloride 400 microgram modified release capsule bottle

glaxosmithkline australia pty ltd - dutasteride, quantity: 500 microgram; tamsulosin hydrochloride, quantity: 400 microgram - capsule, modified release - excipient ingredients: maize starch; carrageenan; gelatin; purified talc; butylated hydroxytoluene; iron oxide yellow; titanium dioxide; iron oxide red; glycerol; medium chain triglycerides; potassium chloride; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); purified water; triethyl citrate; lecithin; glyceryl caprylate/caprate; sunset yellow fcf; carnauba wax; hypromellose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - doubluts is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (bph).

SPIRIVA RESPIMAT tiotropium 2.5 micrograms/actuation solution for inhalation cartridge (with dose indicator) Australia - English - Department of Health (Therapeutic Goods Administration)

spiriva respimat tiotropium 2.5 micrograms/actuation solution for inhalation cartridge (with dose indicator)

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: spiriva respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). spiriva respimat is indicated for the prevention of copd exacerbations.,asthma: spiriva respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

Levothyroxine 50 micrograms per 5 ml oral solution Ireland - English - HPRA (Health Products Regulatory Authority)

levothyroxine 50 micrograms per 5 ml oral solution

mercury pharmaceuticals ltd - levothyroxine sodium - infus/pdr/oral soln - 50 micrograms/5ml - thyroid hormones; levothyroxine sodium